According to the latest research by Persistence Market, the global flu vaccine market is projected to account for a market value of approximatelyUS$ 8 Bn<\/strong>by the end of 2029. Globally, increasing vaccination rate, and focus on preventive rather than reactive, is expected to drive the growth oftheflu vaccine market<\/strong>. Increasing knowledge is due to the awareness drives taken by governments of various countries for the prevention of possible flu outbreaks, particularly in countries, which are more prone to flu pandemic.<\/p>\n Lower cost of flu vaccine plays a major role in the increasing vaccination rate across lower- and middle-income countries. The affordability of flu vaccine is due to World Health Organization’s tie ups with various regional flu vaccine manufacturers as well as major players.<\/p>\n Get Sample Copy of Report @https:\/\/www.persistencemarketresearch.com\/samples\/28720<\/a><\/strong><\/p>\n Company Profiles:<\/strong><\/p>\n The extended efforts by WHO, GAVI, and other organizations to stockpile flu vaccine for possible pandemics has helped improve the vaccination rate. The stockpiling of flu vaccines majorly depends upon various factors such as the possibility of a pandemic, the availability of insurance coverage during a possible pandemic, adequate supply & demand, and research & development.<\/p>\n In developing countries such as India, China, Brazil, etc., local manufacturers tend to develop a high volume of lower-cost vaccines, which helps enhance the reach of flu vaccines among the general population or population that is at a high risk of suffering from flu, which includes children, people aged over 65 years, and pregnant women.<\/p>\n The average time required for manufacturing vaccines and ensuring their availability in the market is around 2 years. However, flu vaccines are manufactured and launched in the market in a period of around a few months only (around 6 months). Thus, the ability of various pharmaceutical and biopharmaceutical companies to manufacture flu vaccines in a shorter duration is among the major drivers of the market.<\/p>\n Get To Know Methodology of Report @https:\/\/www.persistencemarketresearch.com\/methodology\/28720<\/a><\/strong><\/p>\n In the Northern hemisphere, the manufacturing of flu vaccines begins in around February each year depending upon the WHO recommendations, whereas in the Southern hemisphere, it begins in around September. In 2004-2005, the global flu vaccine production capacity was around1.6 billion<\/strong>doses, which increased to around 6.4 billion doses in 2018, thus, indicating an increase in the availability of the same across different regions of the world.<\/p>\n Manufacturers in the flu vaccine market are focusing on expanding their product offering in various countries by undergoing various activities such as partnerships, mergers & acquisitions, launch of new products, approvals, and agreements with various regional manufacturers.<\/p>\n Access Full Report @https:\/\/www.persistencemarketresearch.com\/checkout\/28720<\/a><\/strong><\/p>\n For example, in December 2018, Sanofi developed a new vaccine, dubbed Vaxelis, in partnership with Merck. In 2015, AstraZeneca entered into a license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan.<\/p>\n Persistence Market Research (PMR) has segmented the global flu vaccine market based on the product type, dosage form, distribution channel, and region. In terms of revenue, the quadrivalent flu vaccine segment is expected to be a prominent segment over the forecast period.<\/p>\n By dosage form, intramuscular remains preferred due to higher patient compliance. By distribution channel, sales of flu vaccines are likely to remain higher through institutional sales. The US remains the most lucrative market for flu vaccines market players.<\/p>\n<\/div>\n Explore Extensive Coverage of PMR`sLife Sciences & Transformational Health<\/a>Landscape<\/strong><\/p>\n Molecular Diagnostics Market –<\/strong><\/p>\n Molecular Diagnostics Market<\/a>Segmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.<\/p>\n Next-Generation Sequencing Market –<\/strong><\/p>\n Next Generation Sequencing Market<\/a>Segmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.<\/p>\n Ophthalmology devises Market –<\/strong><\/p>\n Ophthalmology devises Market<\/a>Segmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.<\/p>\n Intravenous Iron Drugs Market –<\/strong><\/p>\n Intravenous (IV) Iron Drugs Market<\/a>Segmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A\/S, Rockwell Medical Technologies, Inc., and Sanofi.<\/p>\n Syndromes Progressive Ataxia Weakness Disorders Market –<\/strong><\/p>\n Treatments forSyndromes of Progressive Ataxia and Weakness Disorders Market<\/a>Segmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.<\/p>\n About us:<\/strong><\/p>\n Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.<\/p>\n To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.<\/p>\n Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.<\/p>\n Contact us:<\/strong><\/p>\n 305 Broadway, 7th Floor <\/p>\n Tags: Flu Vaccines Market Demand<\/a>, Flu Vaccines Market Development<\/a>, Flu Vaccines Market Forecast<\/a>, Flu Vaccines Market Growth<\/a>, Flu Vaccines Market Revenue Share<\/a>, Flu Vaccines Market Size<\/a>, Flu Vaccines Market Supply<\/a>, Flu Vaccines Market Trends<\/a>, Flu Vaccines Market Analysis<\/a><\/p>\n 305 Broadway, 7th Floor Tags:<\/b> 305 Broadway, 7th Floor![\"flu](\"https:\/\/www.persistencemarketresearch.com\/images\/flu-vaccine-market-strategy.jpg\" "\\"Flu")
<\/p>\n\n
\nNew York City, NY 10007
\nUnited States
\nPh.no. +1-646-568-7751
\nE-mail id-sales@persistencemarketresearch.com<\/a>
\nWebsite:https:\/\/www.persistencemarketresearch.com<\/a><\/p>\n<\/div>\n
Contact Information:<\/b><\/p>\n
New York City, NY 10007
United States
Ph.no.<\/strong> +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com<\/a><\/strong>
Website: https:\/\/www.persistencemarketresearch.com<\/a><\/strong><\/p>\n
<\/a>, Extended Distribution<\/a>, Research Newswire<\/a>, English<\/a><\/p>\n<\/div>\n
Contact Information:<\/h3>\n
New York City, NY 10007
United States
Ph.no.<\/strong> +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com<\/a><\/strong>
Website: https:\/\/www.persistencemarketresearch.com<\/a><\/strong><\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/05\/4027-1588609656.png\")
According to the latest research by Persistence Market, the global flu vaccine market is projected to account for a market value of approximately US$ 8 Bn by the end of 2029. Globally, increasing vaccination rate, and focus on preventive rather than reactive, is expected to drive the growth of the flu vaccine market. Increasing knowledge is due to the … Continue reading Flu Vaccines Market to Grow at Stellar CAGR 9.1% During the Forecast Period 2029<\/span><\/a> Continue Reading
<\/p>\n